IgA vasculitis (IgAV) and systemic sclerosis (SSc) are systemic autoimmune diseases with significant skin involvement but distinct underlying mechanisms. In IgAV, acute skin inflammation is driven by innate immune cells, whereas a progressive skin fibrosis is a hallmark of SSc. In IgAV, research on innate immune cells like natural killer (NK) cells is limited, especially in adults, and biomarkers predicting organ involvement are needed. In contrast, in SSc there are limited treatment options to halt fibrosis, which is driven by fibroblast activation.
We explored different components of the innate immune system as biomarkers in adult IgAV and their potential involvement in disease pathogenesis. The research findings suggested a presence of interferon signature in skin-limited IgAV patients and a decrease in NK cell cytotoxic and immunomodulatory function in IgAV patients with nephritis. Furthermore, RNAseq of IgAV patients’ skin suggested deregulation of several proteins linked to the innate immune response, including different adipokines and acute-phase proteins. Most of these were found to be elevated in IgAV patients' serum, correlating with disease severity and organ involvement, thus making them possible biomarkers. Specifically, increased serum LBP was associated with nephritis, while decreased adiponectin and CXCL10 indicated gastrointestinal involvement. Haptoglobin was found to be a novel marker of visceral involvement and relapse in IgAV.
In context of SSc fibrosis the thesis explores cordycepin, 3’deoxyadenosin, as a potential antifibrotic treatment for skin involvement. Using cultures of skin fibroblasts we showed that cordycepin effectively suppresses TGF-β-induced myofibroblast differentiation, which is a key driver of skin fibrosis. This finding opens the possibility of developing new antifibrotic therapies, which are currently very limited.
This research advances the understanding of immune mechanisms in IgAV, identifies novel biomarkers, and proposes a new therapy for SSc, emphasizing the importance of targeted approaches in treating systemic autoimmune diseases.
|